文献知网节
  • 记笔记

Chimeric T regulatory cells for type 1 diabetes treatment

Alexei SavinovIlian RadichevKurt GriffinDavid Scott

Sanford Research, University of South DakotaDepartment of Medicine, Uniformed Services University

摘要:Type 1 Diabetes( T1 D) typically presents in childhood with profound insulin deficiency due to the autoimmune destruction of β cells in pancreatic islets of Langerhans. In susceptible individuals, defective immune tolerance permits development of autoreactive T effector lymphocytes, which eliminate β cells directly. Thus, restoration of immune tolerance is the major prerequisite for any successful T1 D therapy. A major mechanism governing maintenance of immune homeostasis and peripheral tolerance is the suppression of autoreactive T effectors by regulatory T cells, Tregs. Impaired Tregs(both numerically and functionally) are widely believed to underlie the initiation and progression of T1 D auto-immunit y. Addressing this problem, we attempt to develop a novel Treg-based therapy for T1 D. Here we report engineering and in vitro testing of Islet-Specific Chimeric Antigen Receptor-bearing Tregs(ISCAR Tregs). We designed the recognition part of IS-CAR consisting of a single-chain fragment(scFv) from an antibody specific for the human pancreatic endocrine marker HPi2, which we confirmed to recognize human, but not mouse β cells by FACS and immunofluorescence. This scFv was fused to a flexible linker, a trans-membrane domain, CD28 co-stimulatory, and CD3ζ activation domains. The resulted construct was cloned into retroviral vector pRetroX-IRES-ZsGreen1, which was used for transfection of different subpopulations of human T cells(total CD3+, CD4+, CD8+, and CD4+, CD25+, GITR+ Tregs) pre-sorted from the peripheral blood of healthy human donors. Our characterization of expanded IS-CAR-bearing T cells show that they are readily activated and tend to proliferate in co-cultures with human(βLox5) but not mouse(NIT-1) islet cells, thus, confirming the specificity of our IS-CAR. Additionally, we show that the number of Granzyme B+ T cells increase after co-culturing of IS-CAR-transduced total CD3+ cells with βLox5. Furthermore, we tested the ability of our IS-CAR to activate a functional response in IS-CAR+CD8+ T cells in a degranulation assay observing an increase of LAMP-1 levels after co-culturing with human islet cells. In sorted CD4+CD25+ Tregs we observed an increase of Foxp3, IL-10 and TGFβ levels in IS-CAR+ when compared to Mock(empty vector) transduced or IS-CAR-cells. Overall, our results demonstrate specificity of our IS-CAR construct toward islet cells, and provide in vitro evidence of sustained functionality of human IS-CAR bearing Tregs.
会议名称:

Grand Challenges in Immunology: Immunotherapy for Cancer and Beyond——The 2nd CMI-NI Joint Conference

会议时间:

2019-06-11

会议地点:

中国山东青岛

  • 专辑:

    医药卫生科技

  • 专题:

    内分泌腺及全身性疾病

  • DOI:

    10.26914/c.cnkihy.2019.013492

  • 分类号:

    R587.1

  • 手机阅读
    即刻使用手机阅读
    第一步

    扫描二维码下载

    "移动知网-全球学术快报"客户端

    第二步

    打开“全球学术快报”

    点击首页左上角的扫描图标

    第三步

    扫描二维码

    手机同步阅读本篇文献

  • CAJ下载
  • PDF下载

下载手机APP用APP扫此码同步阅读该篇文章

下载:2 页码:92 页数:1 大小:147k

引文网络
  • 参考文献
  • 引证文献
  • 共引文献
  • 同被引文献
  • 二级参考文献
  • 二级引证文献
  • 批量下载
相关推荐
  • 相似文献
  • 读者推荐
  • 相关基金文献
  • 相关法规
  • 关联作者
  • 相关视频